Cargando…
Author Correction: Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease
Autores principales: | Lidberg, Kevin A., Annalora, Andrew J., Jozic, Marija, Elson, Daniel J., Wang, Lu, Bammler, Theo K., Ramm, Susanne, Monteiro, Maria Beatriz, Himmelfarb, Jonathan, Marcus, Craig B., Iversen, Patrick L., Kelly, Edward J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128877/ https://www.ncbi.nlm.nih.gov/pubmed/34002000 http://dx.doi.org/10.1038/s41598-021-90075-z |
Ejemplares similares
-
Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease
por: Lidberg, Kevin A., et al.
Publicado: (2021) -
Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
por: Novak, James S., et al.
Publicado: (2018) -
Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
por: Novak, James S., et al.
Publicado: (2018) -
Author Correction: Systematic evaluation of 2′-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro
por: Chen, Suxiang, et al.
Publicado: (2020) -
A k-mer based transcriptomics approach for antisense drug discovery targeting the Ewing’s family of tumors
por: Annalora, Andrew J., et al.
Publicado: (2018)